| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | President, CEO, and Chairman, Director | Common Stock | 5.92M | $23.7M | $4.00 | Jun 5, 2024 | Held by JPM Partners LLC |
| Atea Pharmaceuticals, Inc. | President, CEO, and Chairman, Director | Restricted Stock Units | 347K | $1.33M | $3.85 | Jan 31, 2024 | Direct |
| Atea Pharmaceuticals, Inc. | President, CEO, and Chairman, Director | Common Stock | 117K | $466K | $4.00 | Jun 5, 2024 | Direct |
| Atea Pharmaceuticals, Inc. | President, CEO, and Chairman, Director | Stock Option (Right to Buy) | 448K | Jan 31, 2024 | Direct | ||
| Kezar Life Sciences, Inc. | Director | Stock Option (Right to Buy) | 26K | Jun 28, 2021 | Direct | ||
| ABG Acquisition Corp. I | Director | Class B ordinary shares | 0 | Mar 1, 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals, Inc. | Jun 5, 2024 | 1 | -$4.02K | 4 | Jun 7, 2024 | President, CEO, and Chairman, Director |
| AVIR | Atea Pharmaceuticals, Inc. | Jan 31, 2024 | 4 | -$219K | 4 | Feb 2, 2024 | President, CEO, and Chairman, Director |
| ABGI | ABG Acquisition Corp. I | Mar 1, 2023 | 1 | $0 | 4 | Mar 3, 2023 | Director |
| AVIR | Atea Pharmaceuticals, Inc. | Jan 31, 2023 | 2 | $0 | 4 | Feb 2, 2023 | President, CEO, and Chairman, Director |
| AVIR | Atea Pharmaceuticals, Inc. | Jan 31, 2022 | 1 | $0 | 4 | Feb 2, 2022 | President, CEO, and Chairman, Director |
| KZR | Kezar Life Sciences, Inc. | Jun 28, 2021 | 1 | $0 | 4 | Jun 30, 2021 | Director |